Clinical Trial Update: Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Tositumomab with I-131-tositumomab in patients with relapsed indolent non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Iodine-131-tositumomab (Iodine-131-tositumomab)
• Tositumomab (tositumomab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED